Table 1 Cohort characteristics at baseline
Predictor | Level | No treatment interruption n (%) | ≥90 day treatment interruption n (%) |
|---|---|---|---|
n = 30,472 | n = 10,162 | ||
Sex | Female | 14,785 (48.5) | 4835 (47.6) |
Male | 15,675 (51.4) | 5326 (52.4) | |
Age (years) | <20 | 1601 (5.3) | 481 (4.7) |
20–39 | 18,408 (60.4) | 6217 (61.2) | |
40–59 | 7181 (23.6) | 1877 (18.5) | |
60+ | 318 (1.0) | 67 (0.7) | |
WHO stage at ART initiation | 1 | 2704 (8.9) | 980 (9.6) |
2 | 2862 (9.4) | 1063 (10.5) | |
3 | 15,317 (50.3) | 5083 (50.0) | |
4 | 9001 (29.5) | 2825 (27.8) | |
CD4 count at ART initiation (cells/μL) | <200 | 13,182 (45.3) | 3864 (38.0) |
200–350 | 4000 (13.1) | 1348 (13.3) | |
>350 | 1304 (4.3) | 450 (4.4) | |
Marital status | Not married | 13,517 (44.4) | 4613 (45.6) |
Married | 15,945 (52.3) | 5343 (52.6) | |
Region | Africa | 6189 (20.3) | 1996 (19.6) |
Asia | 24,281 (79.7) | 8166 (80.4) |